Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Phosphorylated α-synuclein in Parkinson's disease.

Wang Y, Shi M, Chung KA, Zabetian CP, Leverenz JB, Berg D, Srulijes K, Trojanowski JQ, Lee VM, Siderowf AD, Hurtig H, Litvan I, Schiess MC, Peskind ER, Masuda M, Hasegawa M, Lin X, Pan C, Galasko D, Goldstein DS, Jensen PH, Yang H, Cain KC, Zhang J.

Sci Transl Med. 2012 Feb 15;4(121):121ra20. doi: 10.1126/scitranslmed.3002566.

2.

CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders.

Mondello S, Constantinescu R, Zetterberg H, Andreasson U, Holmberg B, Jeromin A.

Parkinsonism Relat Disord. 2014 Apr;20(4):382-7. doi: 10.1016/j.parkreldis.2014.01.011. Epub 2014 Jan 22.

PMID:
24507721
3.

Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies.

Foulds PG, Yokota O, Thurston A, Davidson Y, Ahmed Z, Holton J, Thompson JC, Akiyama H, Arai T, Hasegawa M, Gerhard A, Allsop D, Mann DM.

Neurobiol Dis. 2012 Jan;45(1):188-95. doi: 10.1016/j.nbd.2011.08.003. Epub 2011 Aug 10.

4.

Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis.

Sako W, Murakami N, Izumi Y, Kaji R.

Mov Disord. 2014 Nov;29(13):1599-605. doi: 10.1002/mds.26036. Epub 2014 Sep 25.

PMID:
25258345
5.

α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.

Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C, Schlossmacher MG.

Lancet Neurol. 2011 Mar;10(3):230-40. doi: 10.1016/S1474-4422(11)70014-X. Erratum in: Lancet Neurol. 2011 Apr;10(4):297.

PMID:
21317042
6.

Reduced α-synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity.

van Dijk KD, Bidinosti M, Weiss A, Raijmakers P, Berendse HW, van de Berg WD.

Eur J Neurol. 2014 Mar;21(3):388-94. doi: 10.1111/ene.12176. Epub 2013 Apr 30.

PMID:
23631635
7.

Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.

Tong J, Wong H, Guttman M, Ang LC, Forno LS, Shimadzu M, Rajput AH, Muenter MD, Kish SJ, Hornykiewicz O, Furukawa Y.

Brain. 2010 Jan;133(Pt 1):172-88. doi: 10.1093/brain/awp282. Epub 2009 Nov 10.

PMID:
19903734
8.

Phosphorylated α-synuclein in Parkinson's disease: correlation depends on disease severity.

Stewart T, Sossi V, Aasly JO, Wszolek ZK, Uitti RJ, Hasegawa K, Yokoyama T, Zabetian CP, Leverenz JB, Stoessl AJ, Wang Y, Ginghina C, Liu C, Cain KC, Auinger P, Kang UJ, Jensen PH, Shi M, Zhang J.

Acta Neuropathol Commun. 2015 Jan 31;3:7. doi: 10.1186/s40478-015-0185-3.

9.

CSF α-synuclein does not differentiate between parkinsonian disorders.

Aerts MB, Esselink RA, Abdo WF, Bloem BR, Verbeek MM.

Neurobiol Aging. 2012 Feb;33(2):430.e1-3. doi: 10.1016/j.neurobiolaging.2010.12.001. Epub 2011 Jan 13.

10.

Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.

Hall S, Öhrfelt A, Constantinescu R, Andreasson U, Surova Y, Bostrom F, Nilsson C, Håkan W, Decraemer H, Någga K, Minthon L, Londos E, Vanmechelen E, Holmberg B, Zetterberg H, Blennow K, Hansson O.

Arch Neurol. 2012 Nov;69(11):1445-52.

PMID:
22925882
11.

Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis.

Eusebi P, Giannandrea D, Biscetti L, Abraha I, Chiasserini D, Orso M, Calabresi P, Parnetti L.

BMJ Open. 2016 Jun 13;6(6):e011113. doi: 10.1136/bmjopen-2016-011113. Review.

12.

Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression.

Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Kim HM, Leverenz JB, Montine TJ, Ginghina C, Kang UJ, Cain KC, Wang Y, Aasly J, Goldstein D, Zhang J.

Ann Neurol. 2011 Mar;69(3):570-80. doi: 10.1002/ana.22311. Epub 2011 Mar 11.

13.

Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis.

Gao L, Tang H, Nie K, Wang L, Zhao J, Gan R, Huang J, Zhu R, Feng S, Duan Z, Zhang Y, Wang L.

Int J Neurosci. 2015;125(9):645-54. doi: 10.3109/00207454.2014.961454. Epub 2014 Oct 2. Review.

PMID:
25202803
14.

DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease.

Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Leverenz JB, Baird G, Montine TJ, Hancock AM, Hwang H, Pan C, Bradner J, Kang UJ, Jensen PH, Zhang J.

Brain. 2010 Mar;133(Pt 3):713-26. doi: 10.1093/brain/awq008. Epub 2010 Feb 15.

15.

Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression.

Song YJ, Halliday GM, Holton JL, Lashley T, O'Sullivan SS, McCann H, Lees AJ, Ozawa T, Williams DR, Lockhart PJ, Revesz TR.

J Neuropathol Exp Neurol. 2009 Oct;68(10):1073-83. doi: 10.1097/NEN.0b013e3181b66f1b.

PMID:
19918119
16.
17.

Enteric GFAP expression and phosphorylation in Parkinson's disease.

Clairembault T, Kamphuis W, Leclair-Visonneau L, Rolli-Derkinderen M, Coron E, Neunlist M, Hol EM, Derkinderen P.

J Neurochem. 2014 Sep;130(6):805-15. doi: 10.1111/jnc.12742. Epub 2014 Jun 6.

18.

Neurofilament light chain level in cerebrospinal fluid can differentiate Parkinson's disease from atypical parkinsonism: Evidence from a meta-analysis.

Sako W, Murakami N, Izumi Y, Kaji R.

J Neurol Sci. 2015 May 15;352(1-2):84-7. doi: 10.1016/j.jns.2015.03.041. Epub 2015 Apr 7.

PMID:
25868897
19.

Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease.

Parnetti L, Chiasserini D, Persichetti E, Eusebi P, Varghese S, Qureshi MM, Dardis A, Deganuto M, De Carlo C, Castrioto A, Balducci C, Paciotti S, Tambasco N, Bembi B, Bonanni L, Onofrj M, Rossi A, Beccari T, El-Agnaf O, Calabresi P.

Mov Disord. 2014 Jul;29(8):1019-27. doi: 10.1002/mds.25772. Epub 2014 Jan 16.

20.

A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein.

Landeck N, Hall H, Ardah MT, Majbour NK, El-Agnaf OM, Halliday G, Kirik D.

Mol Neurodegener. 2016 Aug 22;11(1):61. doi: 10.1186/s13024-016-0125-0.

Supplemental Content

Support Center